Towler DA.The osteogenic-angiogenic interface: novel insights into the biology of bone formation and fracture repair.Curr Osteoporos Rep. 2008 Jun;6(2):67-71
Cheng SL, Shao JS, Cai J, Sierra OL, Towler DA. Msx2 exerts bone anabolism via canonical Wnt signaling. J Biol Chem. 2008 Jul 18;283(29):20505-22
Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, and Towler DA. “Msx2 Promotes Cardiovascular Calcification By Activating Paracrine Wnt Signals.” Journal of Clinical Investigation 2005; Vol 115(5):1210-1220
Cheng, S-L, Shao JS, Charlton-Kachigian N, Loewy AP, Towler DA. “Msx2 Promotes Osteogenesis and Suppresses Adipogenic Differentiation of Multipotent Mesenchymal Progenitors.” J Biol Chem 2003; 278, 45969-45977
Bidder M, Shao J-S, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA. Osteopontin Transcription in Aortic Vascular Smooth Muscle Cells is Controlled by Glucose – Regulated USF and AP1 Activities. J Biol Chem 2002; 277 (46):44485-96
Ogawa D, Stone JF, Takata Y, Blaschke F, Chu VH, Towler DA, Law RE, Hsueh WA, and Bruemmer D. “Liver X Receptor Agonists inhibit cytokine-induced Osteopontin Expression in Macrophages through Interference with Activator Protein-1 Signaling Pathways.” Circulation Research 2005; 96, e359-e367
Lai CF, Seshadri V, Huang K, Shao JS, Cai J, Vattikuti R, Schumacher A, Loewy AP, . Denhardt DT, Rittling SR, and Towler DA. “An Osteopontin – NADPH Oxidase Signaling Cascade Promotes Pro-Matrix Metalloproteinase 9 Activation In Aortic Mesenchymal Cells” Submitted
Select Invited PublicationsShao JS, Cai J and Towler DA. “ Molecular Mechanisms of Vascular Calcification: Lessons Learned From The Aorta.” Arteriosclerosis, Thrombosis, and Vascular Biology 2006; Vol 26, In press
Towler DA, Shao JS, Cheng SL, Pingsterhaus JM and Loewy AP. “Osteogenic Regulation of Vascular Calcification.” Annals of the New York Academy of Sciences 2006; In press
Towler DA. Inorganic Pyrophosphate: A Paracrine Regulator of Vascular Calcification and Smooth Muscle Phenotype. Arterioscler Thromb Vasc Biol 2005; 25(4):651-4
Vatikutti R, Towler DA. “Osteogenic Regulation of Vascular Calcification: An Early Perspective.” Am J Physiol Endocrinol Metab 2004; 286, E686-E696
Select Books and Book ChaptersTowler DA and Demer LL. “Vascular Calcification” Primer on the Metabolic Bone Diseases & Disorders of Mineral Metabolism, Chapter 79, 6th Edition, In press
Towler DA and Clemens T. “Vitamin D and Cardiovascular Medicine” Invited book chapter, in Vitamin D, David Feldman, Francis Glorieux, &J. Wesley Pike, Eds., Elsevier, San Diego, CA, 2nd Edition, 889-910, 2005
Towler DA. Use of Cultured Osteoblastic Cells to Identify and Characterize Transcriptional Regulatory Elements, In: Principles of Bone Biology, JP Bilezikian, LG Raisz, & GA Rodan, Eds, Academic Press, San Diego CA 1996; 1173-1188
Patents1. Novel Peptide Substrates and Inhibitors, US Patent #4.709.012,
co-inventor with S.P. Adams and L. Glaser, Washington University and Monsanto.
2. Novel Peptide Inhibitors, European Patent #87870110.1, Aug. 87 Brussels, Belgium, same co-inventors and affiliates as in #1
3. Novel Peptide Substrates, European Patent #87870109.3, Aug. 87 Brussels, Belgium, same co-inventors and affiliates as in #1
4. “Androgen Receptor Modulators and Methods of Use Thereof”. Issued: November 11, 2003. United States Patent Number: 6,645,974 Inventors: Hutchinson; John H; Breslin; Michael J; Rodan; Gideon A; Sahoo; Soumya P; Duggan; Mark E; Harada; Shun-Ichi ; Schmidt; Azriel ; Halczenko; Wasyl; Towler, Dwight A. Assignee: Merck and Co., Inc. (Rahway, NJ)
5. “DNA molecules encoding Macaca mulatta androgen receptor”. Filed, patent pending.United States Patent Application Number: 20040254105. Published 16 December, 2004. Inventors: Towler, Dwight A.; Cheng, Fang. Assignee: Merck and Co., Inc. (Rahway, NJ)
For more articles and abstracts, take this off-site link to the National Library of Medicine
Pub Med page for Dr. Dwight A. Towler